Genmab AS

Genmab AS EBITDA Margin

The EBITDA Margin of Genmab AS (GMAB) as of Nov 22, 2026 is 33.60 %. In the previous year, EBITDA Margin was 31.14 % — a change of 7.91% (higher).

EBITDA Margin

33.60 %

YoY

7.91%

Last updated:

EBITDA Margin of Genmab AS is 2025 33.60 % . EBITDA Margin of Genmab AS was 2024 31.14 % . It decreases by 7.91% higher compared to the previous year.

The Genmab AS EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
45.63 USD
Jan 1, 2019
49.16 USD
Jan 1, 2020
62.44 USD
Jan 1, 2021
35.08 USD
Jan 1, 2022
43.21 USD
Jan 1, 2023
32.30 USD
Jan 1, 2024
31.14 USD
Jan 1, 2025
33.60 USD
The Genmab AS EBITDA Margin history
YEAREBITDA MarginYoY
33.60 %+7.91%
31.14 %-3.59%
32.30 %-25.24%
43.21 %+23.15%
35.08 %-43.81%
62.44 %+27.00%
49.16 %+7.75%
45.63 %-19.71%
56.83 %-1.98%
57.97 %-10.07%
64.46 %+106.72%
31.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

EBITDA Margin of Genmab AS is 33.60 % in 2025.

EBITDA Margin of Genmab AS changed from 31.14 % to 33.60 %, representing a 7.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Genmab AS since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Genmab AS with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genmab AS

All Key Metrics — Genmab AS